Persly, an AI-based healthcare startup, has been selected for an R&D project under the Ministry of SMEs and Startups' technology startup support program, TIPS. As a result, Persly will receive up to 700 million won in R&D funding over the next two years.
TIPS is a startup growth technology development project funded by the Ministry of SMEs and Startups, operated in collaboration with global venture capital firms. Pursley's project was selected through a recommendation from Antler Korea, the operator of TIPS.
Pursley is developing artificial intelligence (AI) predictive technology to detect cancer survivors' risk of recurrence early. To address the limitations of existing regular checkups, the system allows patients to input their daily symptoms through a mobile app. The AI analyzes these symptoms, scores their risk of recurrence, and provides notifications and referrals to hospitals if a risk is detected.
As of 2023, the number of cancer survivors in Korea is estimated at approximately 2.59 million. It is known that approximately 70% of cancer recurrence patients seek medical attention only after experiencing symptoms. Pursley expects to increase early detection rates, reduce treatment costs, and improve survival rates by utilizing self-reported prognosis markers (ePROM)-based data and AI analysis.
The core of this R&D project is to improve the accuracy of cancer recurrence prediction models. Pursley aims to utilize collected patient data to refine its AI algorithms and achieve predictive accuracy comparable to that of global cancer specialists.
In addition, we plan to strengthen our early detection system by expanding collaboration with local governments, local health centers, and life insurance companies, and expand our business areas by developing insurance products for cancer patients.
Pursley Co-CEO Namgung Hyun stated, “Through this TIPS project, we will build an AI-based service that encompasses health management after cancer treatment,” and “We will grow into a technology company that supports the entire life cycle of cancer patients.”
You must be logged in to post a comment.